🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s

    Incyte

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  2. Revlimid 2.5 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 25 mg hard capsules, SOLDESAM 0,2% gocce orali, soluzione, Kyprolis 60 mg powder for solution for infusion

    Fondazione Telethon ETS

    PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT

    phase 3 small molecule active

    1 trial

  3. Revlimid 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, VELCADE 3.5 mg powder for solution for injection, DEXAMETHASONE , Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 10 mg hard capsules, DARZALEX 1800 mg solution for injection

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  4. Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules,

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 3 small molecule active

    1 trial

  5. Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib

    Syndax Pharmaceuticals

    Newly Diagnosed AML with an NPM1 mutation

    phase 3 small molecule active

    1 trial

  6. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Genotype 1 Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  7. Rilvegostomig, DS-8201a, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CARBOPLATIN, DOCETAXEL, PACLITAXEL

    AstraZeneca AB

    HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  8. Rilvegostomig, TEGAFUR, GLUCOSE, INFLIXIMAB, CAPECITABINE, CISPLATIN, MYCOPHENOLATE MOFETIL, TEGAFUR, CAPECITABINE, GEMCITABINE, SODIUM CHLORIDE

    AstraZeneca AB

    Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)

    phase 3 small molecule active

    1 trial

  9. Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  10. Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  11. Rimegepant Placebo, VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate

    Pfizer Australia Pty Ltd

    Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  12. Risankizumab, Placebo for Risankizumab Solution for injection in prefilled syringe, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  13. Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  14. Ritlecitinib tosilate, Placebo to match ritlecitinib 50 mg, Ritlecitinib, Placebo to match ritlecitinib 30 mg

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  15. Ritlecitinib tosilate, Ritlecitinib Tosilate

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  16. RoActemra 20 mg/mL concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Neulasta 6 mg solution for injection, AZD0486, RoActemra 20 mg/mL concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Ribodoxo® 2 mg/ml Injektionslösung, Prednison 20 mg GALEN®, AZD0486, Endoxan 500 mg, poeder voor oplossing voor injectie, Ruxience 500 mg concentrate for solution for infusion

    AstraZeneca AB

    Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  17. Rocatinlimab, Placebo for AMG 451

    Amgen

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  18. Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®)

    Chiesi Farmaceutici S.p.A

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  19. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  20. Ropivacaína Altan 2 mg/ml solución inyectable EFG, Adrenalina B. Braun 1 mg/ml Solución Inyectable

    The George Institute

    lumbar arthrodesis

    phase 3 small molecule active

    1 trial

  21. Rosuvastatin Placebo, MK-0616 (Enlicitide chloride) Placebo, MK-0616, ROSUVASTATIN

    Merck Sharp and Dohme

    Hyperlipidemia

    phase 3 small molecule active

    1 trial

  22. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Lacuna Pharma Pty Ltd

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  23. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Hoffmann-La Roche

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  24. Rukobia 600 mg prolonged-release tablets

    ViiV Healthcare Pty Ltd

    Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources